期刊文献+

持续性心房颤动患者无症状心房颤动的发生情况及影响因素 被引量:6

The incidence of asymptomatic atrial fibrillation and the influence factors in persistent atrial fibrillation patients
原文传递
导出
摘要 目的分析持续性心房颤动(房颤)患者中无症状房颤的发生情况及影响因素。方法收集经24h动态心电图监测确诊的持续性房颤患者82例,观察症状的有无及发生比例。经抗心律失常药物治疗3个月后复查24h动态心电图监测,观察症状的变化情况。采用多元logistic回归分析持续性房颤症状与临床特征的相关性。结果82例患者中34例(42%)无症状房颤发作,48例有症状房颤发作。应用抗心律失常药物治疗3个月后,48例有症状患者中31例症状完全消失,其中4例转复为窦性心律,27例为无症状房颤发作。34例无症状患者中,5例转复为窦性心律,24例仍为无症状房颤发作。持续性房颤中有症状和无症状患者年龄,瓣膜病比较差异有统计学意义(P〈0.05)。其症状与瓣膜病呈正相关(b=1.959,P=0.001),与年龄呈负相关(b=-0.837,P=0.032)。结论持续性房颤患者中无症状房颤的发生率较高。抗心律失常药物既可减少房颤发作,又可减少房颤症状。高龄和非瓣膜病房颤患者易发生无症状房颤。 Objective To investigate the incidence of asymptomatic atrial fibrillation(AF)and the influence factors in patients with persistent AF. Methods A total of 82 consecutive patients with 24 h Halter monitoring identified persistent AF were observed to analyze the incidence of asymptomatic AF. 24 h Hoher moni- toring was performed again after three months' treatment with antiarrythmic drugs in order to identify the inci- dence of asymptomatic AF. Multivariate logistic regression was applied for analyzing the correlation between symptoms and clinical features. Results Thirty-four patients (42%)were asymptomatic,24 patients were symp- tomatic. After antiarrythmic drugs therapy for three months, 31 patients among 48 symptomatic patients, were completely asymptomatic, 4 were converted to sinus rhythm, 27 were asymptomatic atrial fibrillation. In 34 asymptomatic patients, 5 were converted to sinus rhythm, 24 remain asymptomatic atrial fibrillation. Significant differences were found between symptomatic and asymptomatic patients with persistent AF between age and val- vular heart disease ( P 〈 0. 05 ). Symptoms were positively with valvular heart disease ( b = 1. 959, P = O. O01 ), and negatively with age( b = - 0. 837,P = 0. 032). Conclusion The incidence of asymptomatic persistent AF was high. Antiarrythmic drugs could not only relieve the episodes of AF, but also the symptoms of AF. Elderly and nonvalvular atrial fibrillation(NVAF) patients were often asymptomatic.
出处 《中华心律失常学杂志》 2010年第3期200-203,共4页 Chinese Journal of Cardiac Arrhythmias
关键词 持续性心房颤动 无症状心房颤动 临床特征 Persistent atrial fibrillation Asymptomatic atrial fibrillation Clinical features
  • 相关文献

参考文献10

  • 1Robert W,Richard L.Asymptomatic atrial fibrillation.Progress in Cardiovascular Diseases,2005,2:79-87.
  • 2Dewar RI,Lip GY.Identification,diagnosis and assessment of atrial fibrillation.Heart,2007,93:25-28.
  • 3Flaker GC,Belew K,Beckman K,et al.Asymptomatic atrial fibrillation:demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.Am Heart J,2005,149:657-663.
  • 4Savelieta 1,Paquette M,Dorian P,et al.Quality of life in patients with silent atrial fibrillation.Heart,2001,85:216-217.
  • 5Frykman V,Frick M,Jensen-Urstad M,et al.Asymptomatic versus symptomatic persistent atrial fibrillation:clinical and noninvasive characteristics.J Intern Med,2001,250:390-397.
  • 6Blackshear JL,Kopecky SL,Litin SC,et al.Management of atrial fibrillation in adults:prevention of thromboembolism and symptomatic treatment.Mayo Clin Proc,1996,71:150-160.
  • 7Israel CW,Gronefeld G,Ehrlich JR,et al.Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device:Implications for optimal patient care.J Am Coll Cardiol,2004,43:47-52.
  • 8毕亚艳,李智博,黄永麟.无症状心房颤动的临床意义及处理[J].中华心律失常学杂志,2006,10(5):361-363. 被引量:1
  • 9Humphries KH,Kerr CR,Connolly S J,et al.New-onset atrial fibrillation sex differences in presentation,treatment and outcome.Circulation,2001,103:2365-2370.
  • 10Sugishita K,Shiono E,Sugiyama T,et al.Diatetes influences the cardiac symptoms related to atrial fibrillation.Circ J,2003,67:835-838.

二级参考文献16

  • 1张殿新,黄岚,张荣庆,程何祥,王海昌,郭文怡,刘兵,李伟杰.血管紧张素Ⅱ对人心房肌细胞内Ca^(2+)的影响及替米沙坦的拮抗作用[J].第四军医大学学报,2005,26(5):404-406. 被引量:1
  • 2殷跃辉,刘增长,吴近近,代引,苏立,兰先彬,凌智瑜,杨小渝,罗开良.胺碘酮与氯沙坦、培哚普利联合治疗阵发性心房颤动的前瞻、随机开放研究[J].中华心血管病杂志,2006,34(4):299-302. 被引量:72
  • 3Israel CW,Gronefeld G,Ehrlich JR,et al.Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device:implications for optimal patient care.J Am Coll Cardiol,2004,43:47-52.
  • 4Roche F,Gaspoz JM,Da Costa A,et al.Frequent and prolonged asymptomatic episodes of paroxysmal atrial fibrillation revealed by automatic long-term event recorders in patients with a negative 24-hour Holter.PACE,2002,25:1587-1593.
  • 5Frykman V,Frick M,Jensen-Urstad M,et al.Asymptomatic versus symptomatic persistent atrial fibrillation:clinical and noninvasive characteristics.J Intern Med,2001,250:390-397.
  • 6Sugishita K,Shiono E,Sugiyama T,et al.Diabetes influences the cardiac symptoms related to atrial fibrillation.Circ J,2003,67:835-838.
  • 7Levy S,Maarek M,Coumel P,et al.Characterization of different subsets of atrial fibrillation in general practice in France:The ALFA study.The College of Frenh Cardiologists.Circulation,1999,99:3028-3035.
  • 8Klemm HU,Ventura R,Rostock T,et al.Correlation of symptoms to ECG diagnosis following atrial fibrillation.J Cardiovasc Electrophysiol,2006,17:146-150.
  • 9Hart RG,Pearce LA,Rothbart RM,et al.Stroke with intermittent atrial fibrillation:incidence and predictors during aspirin therapy.Stroke Prevention in Atrial Fibrillation Investigators.J Am Coll Cardiol,2000,35:183-187.
  • 10Defaye P,Dournaux F,Mouton E,for the Aida Multicenter Study Group.Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients:the AIDA study.PACE,1998,21:250-255.

同被引文献37

  • 1韩雅玲,王祖禄.心房颤动患者血栓栓塞并发症的防治[J].中国实用内科杂志,2006,26(2):177-179. 被引量:34
  • 2马长生.房颤抗凝治疗的争议与共识[C].第十届心房颤动国际论坛特别报道,2012.
  • 3Meier B, Palacios I, Windecker $, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obvfate anticoagulation in patfents with atriaf ffbrillatfon[J].Oatheter Cardiovasc Interv, 2005,60(5):417-422.
  • 4马长生.房颤导管消融共识:从欧美到中国[C].2012房颤论坛汇编,2012.
  • 5Ben AhmedH, Chelli M, Selmi K, et al. Atrial fibrillation following coronary artery bypass grafting : Predictors and midterm outcome[J]. Tunis Med. 2012, 90(12):888-892.
  • 6Lee S, Monz BU, Clemens A, et al. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom:a cross-sectional analysis using the General Practice Research Database[J]. BMJ, 2012, 2(6): 312-314.
  • 7Cui QQ, Zhang W, Wang H, et al. Assessment of atrial electromechanical coupling and influential factors in nonrheumatic paroxysmal atrial fibrillation[J]. Clin Cardiol, 2008, 31 (2):74-78.
  • 8Ramanna H, Hauer RN, Wittkampf FH, et al. Identification of the substrate of atrial vulnerability in patients with idiopathic atrial fibrillation[J]. Circulation, 2000, 101(9):995-1001.
  • 9Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure [J]. Circulation, 2003, 107(19): 2493-2498.
  • 10Porter KE, Turner NA, O'Regan DJ. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA[J]. Cardiovascular Research, 2004, 61(4):745-755.

引证文献6

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部